Osiris Therapeutics, Inc. (NASDAQ: OSIR) reports a Q2 loss of $0.30 vs. consensus for $0.11 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE